Literature DB >> 15972518

Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system.

F Ader1, R Le Berre, K Faure, P Gosset, O Epaulard, B Toussaint, B Polack, E Nowak, N B Viget, E Kipnis, B P Guery.   

Abstract

The type III secretion system (TTSS) is a specialized cytotoxin-translocating apparatus of gram-negative bacteria which is involved in lung injury, septic shock, and a poor patient outcome. Recent studies have attributed these effects mainly to the ExoU effector protein. However, few studies have focused on the ExoU-independent pathogenicity of the TTSS. For the present study, we compared the pathogenicities of two strains of Pseudomonas aeruginosa in a murine model of acute lung injury. We compared the CHA strain, which has a functional TTSS producing ExoS and ExoT but not ExoU, to an isogenic mutant with an inactivated exsA gene, CHA-D1, which does not express the TTSS at all. Rats challenged with CHA had significantly increased lung injury, as assessed by the wet/dry weight ratio for the lungs and the protein level in bronchoalveolar lavage fluid (BALF) at 12 h, compared to those challenged with CHA-D1. Consistent with these findings, the CHA strain was associated with increased in vitro cytotoxicity on A549 cells, as assessed by the release of lactate dehydrogenase. CHA was also associated at 12 h with a major decrease in polymorphonuclear neutrophils in BALF, with a proinflammatory response, as assessed by the amounts of tumor necrosis factor alpha and interleukin-1beta, and with decreased bacterial clearance from the lungs, ultimately leading to an increased mortality rate. These results demonstrate that the TTSS has a major role in P. aeruginosa pathogenicity independent of the role of ExoU. This report underscores the crucial roles of ExoS and ExoT or other TTSS-related virulence factors in addition to ExoU.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972518      PMCID: PMC1168600          DOI: 10.1128/IAI.73.7.4263-4271.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

Review 1.  Tissue destruction by neutrophils.

Authors:  S J Weiss
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

2.  Polymorphonuclear leukocyte- and Pseudomonas aeruginosa-induced damage to a human pulmonary epithelial cell line.

Authors:  M M Dunn; M Dunne; D W Kamp
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

3.  Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression.

Authors:  J E Pennington; M G Ehrie
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

Review 4.  ExoU is a potent intracellular phospholipase.

Authors:  Hiromi Sato; Dara W Frank
Journal:  Mol Microbiol       Date:  2004-09       Impact factor: 3.501

5.  An adenylate cyclase-controlled signaling network regulates Pseudomonas aeruginosa virulence in a mouse model of acute pneumonia.

Authors:  Roger S Smith; Matthew C Wolfgang; Stephen Lory
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

6.  Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits.

Authors:  J P Wiener-Kronish; T Sakuma; I Kudoh; J F Pittet; D Frank; L Dobbs; M L Vasil; M A Matthay
Journal:  J Appl Physiol (1985)       Date:  1993-10

7.  Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

Authors:  J F Pittet; M A Matthay; G Pier; M Grady; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

8.  A type I cell-specific protein is a biochemical marker of epithelial injury in a rat model of pneumonia.

Authors:  M C McElroy; J F Pittet; S Hashimoto; L Allen; J P Wiener-Kronish; L G Dobbs
Journal:  Am J Physiol       Date:  1995-02

9.  Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury.

Authors:  I Kudoh; J P Wiener-Kronish; S Hashimoto; J F Pittet; D Frank
Journal:  Am J Physiol       Date:  1994-11

10.  TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins.

Authors:  Karine Faure; Teiji Sawa; Temitayo Ajayi; Junichi Fujimoto; Kiyoshi Moriyama; Nobuaki Shime; Jeanine P Wiener-Kronish
Journal:  Respir Res       Date:  2004-02-12
View more
  20 in total

1.  The sensor kinase KinB regulates virulence in acute Pseudomonas aeruginosa infection.

Authors:  Nikhilesh S Chand; Jenny See-Wai Lee; Anne E Clatworthy; Aaron J Golas; Roger S Smith; Deborah T Hung
Journal:  J Bacteriol       Date:  2011-04-22       Impact factor: 3.490

2.  Type III secretion-dependent modulation of innate immunity as one of multiple factors regulated by Pseudomonas aeruginosa RetS.

Authors:  Irandokht Zolfaghar; David J Evans; Reza Ronaghi; Suzanne M J Fleiszig
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 3.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

4.  Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Authors:  Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller
Journal:  Pediatr Pulmonol       Date:  2013-09-09

Review 5.  Antibiotics as signal molecules.

Authors:  Diego Romero; Matthew F Traxler; Daniel López; Roberto Kolter
Journal:  Chem Rev       Date:  2011-07-25       Impact factor: 60.622

6.  Development of two animal models to study the function of Vibrio parahaemolyticus type III secretion systems.

Authors:  Pablo Piñeyro; Xiaohui Zhou; Lisa H Orfe; Patrick J Friel; Kevin Lahmers; Douglas R Call
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

7.  Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands.

Authors:  Chanez Chemani; Anne Imberty; Sophie de Bentzmann; Maud Pierre; Michaela Wimmerová; Benoît P Guery; Karine Faure
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

8.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

9.  Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice.

Authors:  Jennifer M Scarff; Joanna B Goldberg
Journal:  Clin Vaccine Immunol       Date:  2007-12-19

Review 10.  The type III secretion system of Pseudomonas aeruginosa: infection by injection.

Authors:  Alan R Hauser
Journal:  Nat Rev Microbiol       Date:  2009-09       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.